Task: Answer the following question about the molecule with SMILES [O-][n+]1cccc(C(Cl)=NOC[C@H](O)CN2CCCCC2)c1.
Description: Please describe this drug.
Completion: Arimoclomol is an experimental drug compound developed by CytRx Corporation, a biopharmaceutical company based in Los Angeles, California. The orally administered drug is intended to treat amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig's disease, a neurodegenerative disease with no effective treatment.
Task: Answer the following question about the molecule with {SMILES__description} {SMILES#}.
{#Description|Question|Request!}: {quest#}
{#Result|Answer|Completion!}: {answ#}
[O-][n+]1cccc(C(Cl)=NOC[C@H](O)CN2CCCCC2)c1
C1CCN(CC1)C[C@H](CON=C(C2=C[N+](=CC=C2)[O-])Cl)O
N-[(2R)-2-hydroxy-3-piperidin-1-ylpropoxy]-1-oxidopyridin-1-ium-3-carboximidoylchloride
Please describe this drug.
Arimoclomol is an experimental drug compound developed by CytRx Corporation, a biopharmaceutical company based in Los Angeles, California. The orally administered drug is intended to treat amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig's disease, a neurodegenerative disease with no effective treatment.